Status: Ongoing First registered on: 12/09/2019
Last updated on: 31/12/2019
1. Study identification
EU PAS Register NumberEUPAS31355
Official titleThe Characterization and Comparison of Eosinophilic and Non-eosinophilic Phenotypes of Severe Asthma
Study title acronymEosinophilic and Non-eosinophilic Phenotypes
Study typeObservational study
Brief description of the studyThis cross-sectional study design is the first step to better understand and assess the presence of eosinophilic and non-eosinophilic asthma phenotypes using known constructs of severe asthma epidemiology. Firstly, most likely non-eosinophilic asthma patients will be identified followed by discerning eosinophilic asthma patients with most likely versus likely degrees of confidence. The characteristics of eosinophilic and non-eosinophilic phenotypes will be compared to a benchmark (published results from a similar study population). Data for this study will be sourced from the International Severe Asthma Registry (ISAR). Parallel analyses using a primary care observational database, the Optimum Patient Care Research Database (OPCRD), will be conducted for providing a benchmark for comparison.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre nameOptimum Patient Care Global Limited (OPCG)
Centre locationUK
Details of (Primary) lead investigator
Title Professor
Last name Price
First name David
Is this study being carried out with the collaboration of a research network?
Yes

Optimum Patient Care (OPC)
Respiratory Effectiveness Group (REG)
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
International study

Bulgaria
Canada
Greece
Ireland
Italy
Japan
Korea, Republic of
Kuwait
Spain
United Kingdom
United States
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed01/04/201830/04/2018
Start date of data collection31/08/201815/10/2018
Start date of data analysis01/03/201915/03/2019
Date of interim report, if expected
Date of final study report31/01/2020
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesAstraZeneca50
Charities
Government body
Research councils
EU funding scheme
OtherOPCG50
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 15 Coles Lane
Address line 2 
Address line 3 
CityOakington, Cambridge 
PostcodeCB24 3BA 
CountryUnited Kingdom
Phone number (incl. country code)44-7787-905057 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg
Public Enquiries
Title Professor 
Last name Price 
First name David 
Address line 15 Coles Lane 
Address line 2 
Address line 3 
CityOakington, Cambridge 
PostcodeCB24 3BA 
CountryUnited Kingdom 
Phone number (incl. country code)44-7787-905057 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg 
Top